Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Valproate therapy: predisposition to bone fracture?

S G Pavlakis1, R L Chusid, D P Roye

  • 1Department of Neurology and Pediatrics, North Shore University Hospital, New York University, Manhasset 11030, USA.

Pediatric Neurology
|September 23, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Quantitative Evaluation of Medial Temporal Lobe Morphology in Children with Febrile Status Epilepticus: Results of the FEBSTAT Study.

AJNR. American journal of neuroradiology·2016
Same author

The role of EEG in febrile status epilepticus (FSE).

Brain & development·2009
Same author

Phenomenology of prolonged febrile seizures: results of the FEBSTAT study.

Neurology·2008
Same author

Special needs of the adolescent with epilepsy.

Epilepsia·2002
Same author

Advances in our understanding of early childhood epilepsies: 1999-2000.

Current neurology and neuroscience reports·2002
Same author

Brain imaging in neurobehavioral disorders.

Pediatric neurology·2001

Valproate therapy in children may increase fracture risk. Discontinuing valproate appeared to stop new fractures in one case, suggesting a link between this antiepileptic drug and bone health.

Area of Science:

  • Pediatric Neurology
  • Pharmacology
  • Bone Metabolism

Background:

  • Valproate is a widely used antiepileptic drug in children.
  • Bone health is crucial during pediatric development.
  • Fracture risk can be influenced by various factors including medication.

Observation:

  • A case study identified a 13-year-old girl experiencing 20 fractures between ages 5 and 9 during valproate treatment.
  • No new fractures occurred in this patient after valproate withdrawal over a subsequent 4-year period.
  • Three additional pediatric cases reported multiple fractures during valproate antiepileptic therapy.

Findings:

  • Valproate therapy may be associated with an increased predisposition to fractures in children.
  • The drug's potential role in demineralization warrants further investigation.

Related Experiment Videos

  • This association is observed alongside other known risk factors for bone demineralization.

    • Implications:

    • Clinicians should consider valproate's potential impact on bone density in pediatric patients.
    • Further research is needed to elucidate the mechanism linking valproate to fractures.
    • Monitoring bone health in children on long-term valproate therapy may be advisable.